Company intelligence / Profile preview
HealthBanks Biotech
Irvine, California, United Stateshealthbanks.us ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Phase I trial for PEK fusion protein vaccine in patients with LSIL or HSIL showed the vaccine is safe and well-tolerated and induces a measurable immune response
- Therapeutic areas
- OncologyEndocrinologyRare DiseasesOther
- Modalities
- Stem cellsImmune cellsCell-based therapies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
ThermoGenesisCesca Therapeutics
Beyond the preview
Go deeper on HealthBanks Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HealthBanks Biotech.